An Unexpected Finding
In 1992, Sir Adrian Bird discovered a new protein and named it MECP2. Seven years later, Professor Huda Zoghbi discovered that mutations in MECP2 cause Rett. In 2007, Professor Bird shocked the scientific and Rett communities by showing that Rett symptoms in mice models disappeared upon restoration of MECP2.
This finding changed everything as it suggested a cure was possible. Monica Coenraads launched the Rett Syndrome Research Trust in 2008 to focus exclusively on cures. Adrian Bird joined Monica as a founding trustee, a position he holds to this day.
Gene Therapy Consortium
Since the moment RSRT was created, we’ve been optimistic about curing Rett. Fueling our optimism are three key facts: a single gene means we have a clear target, Rett brain cells don’t die, and restoring levels of MECP2 reverses symptoms in mice models.
When we began there was only one option to boost levels of MECP2: gene therapy. Many believed gene therapy for the brain was science fiction. We recognized that it was the wave of the future. Determined to make it a priority, we provided generous funding to drive this approach forward. In 2013, an RSRT-funded study by Gail Mandel, Brian Kaspar, and Adrian Bird showed that gene therapy had reversed symptoms in female Rett mice.
Spurred by the belief that labs with synergistic but varied skill sets would accelerate progress, we conceived the Gene Therapy Consortium in 2014. After scouring the gene therapy landscape we invited gene therapists Brian Kaspar and Steve Gray, and MECP2 experts Stuart Cobb and Gail Mandel to join the Consortium.
The Consortium is one of the most valuable investments we’ve made as it formed the foundation for the Rett programs at Neurogene, Taysha, and Vico.
Gene therapy is one approach to target Rett but it’s not the only approach. We believe the greatest likelihood of achieving cures is to take as many shots on goal as possible.
Roadmap to a Cure 1.0
In 2017 we launched a three-year, $33 million research plan, with the goal of identifying and advancing all possible genetic medicine avenues that address the root cause of Rett.
Our Track Record
Breakthrough discoveries are made in academic labs. But academic scientists are not drug developers — biopharmaceutical companies develop drugs. As Rett syndrome is not low-hanging fruit for biopharma, RSRT functions as a matchmaker and catalyst to derisk and ensure that biopharma picks up programs that we have advanced.
Our track record speaks for itself: Every single company pursuing a genetic medicine for Rett is able to do so because they leveraged discoveries and resources that were advanced with RSRT funding.
Neurogene
NGN-401 was developed by Stuart Cobb with substantial funding from RSRT over the course of a decade. We introduced Cobb to Neurogene’s CEO who subsequently hired him to become the company’s Chief Scientific Officer.
Taysha
TSHA-102, delivers a mini-gene developed by Adrian Bird with RSRT funding. miRARE, which controls MECP2 levels was developed by Steve Gray with RSRT funding.
Beam
The DNA editing program at Beam was fully funded by RSRT. Access to our biorepository of Rett cell lines further enabled this research.
Alcyone
ACTX-101, was developed by Kathrin Meyer and Sanchita Bhatnagar both of whom got their start in Rett with RSRT funding. We introduced the scientists to each other, which enabled their critical collaboration.
Herophilus
Pioneering research funded with millions of dollars by RSRT enabled this approach of reactivating the silent MECP2. RSRT also provided some funding to the company as well as access to our biorepository.
Shape
Landmark RSRT-funded research by the Mandel lab put RNA editing on the map and made it a realistic approach to pursue. Access to our biorepository enabled the company to pursue a Rett program.
Vico
Gail Mandel, scientific founder of Vico, pioneered RNA editing with substantial funding from RSRT over a decade. Access to our biorepository further enabled this program.
Wave
Landmark RSRT-funded research by the Mandel lab put RNA editing on the map and made it a realistic approach to pursue. Access to our biorepository enabled the company to pursue Rett.
Yearly Awards
A list of our research awards from 2008 to 2023.
Publications
A list of scientific publications made possible through our funding.
Our Collaborators
A History of Rett & RSRT
1966
1st article published on Rett in German medical journal
1983
2nd article on Rett published in high-profile neurology journal
1992
MECP2 protein discovered by Adrian Bird
1999
MECP2 mutations identified by Huda Zogbhi as cause of Rett
2007
Adrian Bird discovers Rett symptoms in mice are reversible
2008
Rett Syndrome Research Trust launches
2011
MECP2 Consortium launches
2013
Gail Mandel and Brian Kaspar publish gene therapy results
2014
RSRT Gene Therapy Consortium launches
2017
Roadmap to a Cure launches
2019
Beam joins DNA editing effort
2020
CURE 360 launches
2020
Taysha Gene Therapies announces gene therapy program
2020
Vico Therapeutics announces RNA editing program
2020
Shape Therapeutics announces RNA editing program
2021
Alcyone Therapeutics announces lead MECP2 reactivation program
2021
Herophilus announces lead MECP2 reactivation program
2022
Taysha Gene Therapies announces first gene replacement trial
2022
Neurogene announces gene replacement program
2023
Taysha Gene Therapies doses patient #1 in gene replacement trial
2023
Neurogene doses first two patients
2023
Rett Syndrome Global Registry launches
2024
MECP2 Editing Consortium created
2024
Roadmap to Cures 2.0 announced
Built on decades of scientific advances Roadmap to Cures will select and drive three genetic medicines that attack the root cause of Rett syndrome to clinical trials by 2028.
